ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 18 of 49
Up
УЖМБС 2018, 3(1): 89–98
https://doi.org/10.26693/jmbs03.01.089
Clinical Medicine

The Indicators of Clinical and Laboratory Studies of Patients with Impaired Immunity because of Oncohematological Pathology Determining the Severe Course and Fatal Outcome of Pneumonia

Borisova I. S.
Abstract

The objective of the study was to determine the indicators of clinical and laboratory studies of patients with impaired immunity because of oncohematological pathology determining the severe course and fatal outcome of pneumonia. Materials and methods of research. The authors of research created a computer database with the results of studying 811 patients with impaired immunity. These patients were examined or treated for various nosological forms of oncohematological pathology in the hematological center "City Clinical Multiprofile Hospital No. 4", Dnipro, 2010-2015. The following indicators were studied and analyzed: the age of the patients; form, stage, duration of the disease; number of HT courses; pathogens, pneumonia, the presence of cough and sputum, physical examination data (dry and wet wheezing, percussion data), the time of complaints, body temperature, X-ray data, the course of pneumonia of its complications, heart rate, pulse; laboratory indicators of the blood general analysis, number of leukocytes and neutrophils, immunograms data; accompanying illnesses. The statistical processing of the results was carried out using the methods of descriptive and analytical biostatistics (StatSoftInc., Serial No. AGAR909E415822FA) Microsoft Excel (Office Home Business 2KB4Y-6H9DB-BM47K-749PV-PG3KT). To describe the quantitative traits, the median (Me) interquartile range (25%, 75%) was used to describe the variation of the characteristics. Nonparametric variance analysis of Craskell-Wallis, correlation analysis with calculation of the Spearman rank correlation coefficients (ρ), multiple comparisons were performed with Bonferroni and the Holm corrections. We studied a set of anamnesis, clinical and laboratory signs that could, in complex mathematical analysis, act as factors that determined the poor prognosis of pneumonia in patients with impaired immunity because of oncohematological pathology. To solve the problem, factor analysis was carried out using the method of principal components using varimax rotation. Results of the study identified five groups of factors that caused the severity of the course and the occurrence of a lethal outcome of pneumonia and determined the overall dispersion by 63.3%. The appearance of lethal outcome of pneumonia in patients with impaired immunity because of oncohematological diseases is affected by a number of indicators grouped into five factors: cellular immunity (39.1% in the total variance); neutropenia and the state of phagocytosis (6.96%); anemia (6.5%); humoral immunity (5.75%) and clinical symptoms of pneumonia (4.99). Pneumonia in patients with impaired immunity is a separate nosological form. Disturbance of immunity in patients with pneumonia with oncohematological background had the greatest impact on the occurrence of severe course of pneumonia. The contribution of the immune response to the possibility of a lethal outcome of pneumonia was more than 50% of the total factor influence of the factors identified in the study. Therefore, we should further study the possibilities of treating pneumonia in patients with impaired immunity from the standpoint of the state of the immune response of patients on the background of oncohematological pathology.

Keywords: pneumonia, clinical and laboratory indicators, impaired immunity, factors of poor prognosis

Full text: PDF (Ukr) 314K

References
  1. Borisova ІS. [Anemia as a prognostic factor in patients with pneumonia on the background of oncohematological diseases]. Ukrainskiy medichniy almanakh. 2013; 6 (2): 30-2. [Ukrainian]
  2. Grzhibovskiy AM. [Analysis of nominal data (independent observations)] Ekologiya cheloveka. 2008; 6: 58-68. [Russian]
  3. Voytsekhovskiy VV, Esenina TV, Filatova EA, Makarova NV. [Infectious complications of hemoblastoses during programmed chemotherapy]. Amurskiy meditsinskiy zhurnal. 2016; 2 (14): 20-5. [Russian]
  4. Toropova IYu, Parovichnikova EN, Klyasova GA. [Clinical monitoring of infectious complications in patients with hemoblastosis on the background of programmed chemotherapy]. Gematologiya i transfuziologiya. 2011; 6: 10-20. [Russian]
  5. Lang TA, Sesik M. [How to describe statistics in medicine. A guide for authors, editors and reviewers. 2nd edition]. M: Prakticheskaya meditsina, 2016. 480 p. [Russian]
  6. Nakaz № 128 MOZ Ukraine «Pro zatverdzhennya klіnіchnikh protokolіv nadannya medichnoї dopomogi za spetsіal'nіstyu «Pul'monologіya» vіd 19.03.2007 [Community acquired and nosocomial (hospital) pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antibiotic therapy (guidelines)]. K: Veles, 2007. p 105-46. [Ukrainian]
  7. Yurkin AK, Shchegolev AV, Maksimov AG, Semelev VN. [Features of dynamics of cytokines and immunoglobulins in patients with malignant lymphomas]. Vestnik rossiyskoy voenno-meditsinskoy akademii. 2015; 1 (49): 59-62. [Russian]
  8. Renke AL, Zherer AA, Shlapak IP. [Accompanying treatment of complications of chemotherapy for cancer patients]. Meditsina neotlozhnykh sostoyaniy. 2015; 1: 20-6. [Russian]
  9. Nakaz № 647 MOZ Ukraine «Pro zatverdzhennya protokolіv nadannya medichnoї dopomogi za spetsіal'nіstyu «Onkologіya» vіd 30.07.2010. Standarti dіagnostiki ta lіkuvannya onkologіchnikh khvorikh. Z dopovnennyami zgіdno: Nakazu MOZ Ukraine vіd 30.01.2013 №72; Nakazu MOZ Ukraine vіd 02.11.2015 № 709; Nakazu MOZ Ukraine vіd 02.11.2015 № 711; Nakazu MOZ Ukraine vіd 02.11.2015 № 710; Nakazu MOZ Ukraine vіd 26.06.2014 № 433. [Ukrainian]
  10. Strachunskiy LS, Kozlov SN. [«Glucocorticoid Drugs»] [digital resource] Smolenskaya Gosudarstvennaya Meditsinskaya Akademiya, Kafedra klinicheskoy farmakologii i antimikrobnoy khimioterapii. Available from: www.antibiotic.ru/rus/all/metod/gk. [Russian]
  11. Dmitrieva NV, Bagirova NS, Grigor'evskaya ZV. [Febrile neuroypia in cancer patients]. Farmateka. 2010; 14: 68-77. [Russian]
  12. Abers MS, Musher DM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM: An International Journal of Medicine. 2014 July; 107 (7): 595–6. https://doi.org/10.1093/qjmed/hcu096
  13. Ringdén O, Erkers T, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, Omazic B, Svenberg P, Dahllöf G, Mattsson J, Ljungman P, Remberger M. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013 Aug; 274 (2): 153-62. https://www.ncbi.nlm.nih.gov/pubmed/23432209. https://doi.org/10.1111/joim.12056
  14. Prachi Jain, Jeffrey Klotz, Neil Dunavin. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia Research Reports. 2015; 7: 40-4. https://doi.org/10.1016/j.lrr.2017.04.003
  15. Freifeld AG, Bow EJ, Sepkowitzу KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011; 52 (4): 56. https://www.ncbi.nlm.nih.gov/pubmed/21258094. https://doi.org/10.1093/cid/cir073
  16. Girmenia C, Menichetti F. Current Epidemiology and Prevention of Infectious Complications in Cancer Patients. Eur Oncol Haematol. 2011; 7 (4): 270-7. http://doi.org/10.17925/EOH.2011.07.04.270
  17. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of Symptom Resolution in Patients with Community-Acquired pneumonia. Clinical Infections Diseases. 2000; 31: 1362-7. https://doi.org/10.1086/317495
  18. Mims C, Playfair J, Roitt I, Wakelin D, Williams R. Medical microbiology. Edinburg: Mosby, 2002. 584 p.
  19. Sarai R, Eds J, Armitage O. High Dose Cancer Therapy Pharmacology, Haematopoiesis. Stem Cells. 1992. p 456-72.